# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Sean Lee maintains Gritstone Bio (NASDAQ:GRTS) with a Buy and lowers the price target from $...
Gritstone Bio (NASDAQ:GRTS) reported quarterly losses of $(0.34) per share which missed the analyst consensus estimate of $(0.3...
Paper details vaccine design optimization process of Gritstone's "off-the-shelf" or shared neoantigen vaccine pla...